Project Management Manager, Scientist

Ryan Stewart

Philadelphia, PA ***** 585-***-**** ************@*****.*** LinkedIn

PROFESSIONAL SUMMARY

Experienced Scientist & Project Manager with over a decade of experience in project management and client relations within the biotechnology and pharmaceutical industries. I hold an MBA in Pharmaceuticals and Healthcare Business, which has equipped me with the strategic and operational expertise to lead cross-functional teams and manage complex, high-stakes projects. My goal is to contribute to an organization that is shaping the future of healthcare by streamlining the development and manufacturing processes to deliver better outcomes for patients worldwide. I am enthusiastic about building and scaling enterprises that integrate innovative technologies, world- class leadership, and robust infrastructure to bring therapies from bench to bedside. Through strong stakeholder management, efficient project execution, and a purposeful approach, I aim to continue collaborating with top-tier professionals to accelerate the availability of life-saving treatments. CORE COMPETENCIES

• GMP, GLP, R&D

• Gene therapy manf & testing

• Optimization & Automation

• Assay Transfers

• Validation protocols

• Writing/reviewing LIRs

• Infectious Titer Assays

• Contract creation

• Lean Six Sigma

• Critical thinking

• Troubleshoot issues

• Team-oriented

PROFESSIONAL EXPERIENCE

Bristol Myers Squibb October 2023 – October 2024

Manager, Drug Product and Virial Vector

• Life Cycle Management for Cell Therapy drug products and drug substances

• Drive the qualification and validation for vector release methods using CTL platforms

• Coordinate all aspects for the transition of testing methods from site to site

• Manage the lifecycle of Viral Vector and Drug Product Methods internally and, at contract service providers

Center for Breakthrough Medicines, PA May 2022 – July 2023 Technical Project Manager, Testing and Analytical Services

• Served as liaison between lab personnel, supply chain, finance, master data management, and leadership teams; created and maintained a bill of materials for each assay and client

• Reviewed and approved purchase requests including lab materials and equipment

• Created Visio charts to map out steps and timing in assays to help with capacity estimations

• Provided oversight for laboratory scientists and technicians; assisted in testing quote generation

• Researched, identified, purchased, and maintained new and existing laboratory products and resources

WuXi AppTec, Philadelphia, PA

Associate Scientist/Tech Reviewer, Study Director of Virology Ops July 2017-October 2021

• Scheduled, implemented, and execution of gene therapy testing

• Leader over multiple gene therapy testing units (adenovirus, rAAV, lentivirus)

• Engaged in GMP audits from regulatory bodies (FDA, EMA, PMDA) and client audits

• Wrote and reviewed standard operating procedures (SOPs)

• Trained new study directors and laboratory technicians

• Assisted with development of automation to improve assay performance (Greenbelt project)

• Transferred Assays (Internal/External)

OyaGen, Inc. Rochester, NY April 2016 – June 2017

Laboratory Manager and Senior Technician

• Creation of stable cells lines with expression of fluorescent proteins

• Coordinated with Lab Director, Scientists, Controller, Collaborators and Sales Representatives.

• Created stable clonal cells lines for High Throughput Screens (HTS)

• Operated a liquid handling robot and fluorescence plate reader

• Managed compounds/potential drugs; Cytospin experiments

• Created and maintained social media pages (Oyagen)

• Running single-cycle pseudotyped HIV experiments (ELISA for p24 capsid, viral particle isolation) OyaGen, Inc.Rochester, NY

Technical Associate August 2013-April 2016

• Worked in a team of researchers focused on High Throughput Screens to identify small molecules targeting HIV and Ebola.

• Maintained human cells (suspension cell lines, adherent cell lines, PBMCs)

• Operated liquid handling robotics and fluorescence plate readers

• Gel electrophoresis & Western blotting

• Assisted in assay development and co-immunoprecipitation experiments

• Fluorescence cell imaging

• Plated cells for screening on 96 and 384 well plates

• Maintained and operated standard laboratory equipment EDUCATION

Saint Joseph’s University, Philadelphia, PA Summer 2022-Fall 2024 Master of Business Administration (MBA), Pharmaceutical and Healthcare Business GPA: 3.4/4.0

University of the Sciences, Philadelphia, PA Fall 2019-Spring 2022 Master of Business Administration (MBA), Pharmaceutical and Healthcare Business GPA: 3.7/4.0

Rochester Institute of Technology – Saunders College of Business, Rochester, NY 2016 Accounting for Decision Makers (ACCT.603.01)

Economics and Decision Modeling (ESCB. 705.01)

State University of New York at Oswego 2008-2012

Degree earned: B.A. in Biology

EDUCATION

INSTRUMENTATION/SOFTWARE PROFICIENCY

• WinPREP for JANUSTM Automated Workstation

• Gen5™Synergy 4 Multi-Mode Microplate Reader

• MultiFlo™ FX automated multi-mode reagent dispenser

• MetaMorph® Digital Imaging Software for Olympus Microscope

• Applied Biosystems™ 7500 Real-Time PCR Systems; Image J Software

• Windows and Mac operating systems: Word, Excel, PowerPoint, Project, Visio

• 7500 Fast System with 21 CFR Part 11 Software,Biomek 4000 Automated Liquid Handler

• BioSpectrum® Imaging System: VisionWorks Image Acquisition and Analysis Software RESEARCH/PUBLICATIONS

• Hilimire TA, Bennett RP, Stewart RA, Garcia-Miranda P, Blume A, Becker J, Sherer N, Helms ED, Butcher SE, Smith HC, Miller BL. N-Methylation as a Strategy for Enhancing the Affinity, and Selectivity of RNA-binding Peptides: Application to the HIV-1 Frameshift-Stimulating RNA. ACS Chem Biol. 2015. Oct 23; epub. DOI: 10.1021/acschembio.5b00682.PubMed PMID: 26496521

• Bennett RP, Stewart RA, Mankowski MK, Hogan PA, Hartman TL, Buckheit, Jr. RW, Ptak RG, Salter JD, Morales GA, Smith HC. An Analog of Camptothecin Inactive Against Topoisomerase I is Broadly Neutralizing of HIV-1 Through Inhibition of Vif-Dependent APOBEC3G Degradation. Antiviral Research. 2016. Nov 4; http://dx.doi.org/10.1016/j.antiviral.2016.11.001

• Hilimire T, Chamberlain J, Anokhina V, Bennett R, Swart O, Myers J, Ashton J, Stewart R, Gates K, Featherston A, Helms E, Smith H, Dewhurst S, Miller B. HIV-1 Frameshift RNA-Targeted Compounds Incorporating a Triazole Bioisostere of Disulfide Inhibit Propagation of Replication- Competent and Multi Drug-Resistant HIV in Human Cells. ACS Chemical Biology. 2017

• Polevoda B, Joseph R, Friedman AE, Bennett RP, Greiner R, DeZoysa T, Stewart RA, Smith HC. APOBEC3G DNA Mutagenic Activity and Capacity for HIV-1 Restriction Depends on Whether DNA or RNA Bind to Tyrosine 315. Journal of Biological Chemistry. 2017

• Bennett, R.P.; Finch, C.L.; Postnikova, E.N.; Stewart, R.A.; Cai, Y.; Yu, S.; Liang, J.; Dyall, J.; Salter, J.D.; Smith, H.C.; et al. A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures. Viruses 2021, 13, 52. https://doi.org/ v1301005

Contact this candidate